they performed TBSE in patients with no personal or family history of skin cancer and those with a high risk for skin cancer ( family history of skin cancer; personal history of sunburns, actinic damage, dysplastic nevi, and/or multiple nevi; or fair skin). Participant demographic data were collected including years in practice, location of practice (rural, suburban, urban, or combination) , and practice environment (residency training, academic faculty practice, private practice, outpatient-based hospital clinic, or other). Data were analyzed using standard 2 and 95% confidence intervals.
Of 6500 dermatologists surveyed, 9.6% (623) responded. The literature supports that our study sample size appears to be large enough to make accurate statistical inferences and representative of the surveyed population. In patients with no personal or family history of skin cancer, 86% of dermatologists reported performing TBSE either annually or every 2 to 3 years, 1% of dermatologists reported performing TBSE every 6 months, and 13% of dermatologists reported rarely/never performing TBSE routinely in this population. 5 In comparison, in patients with high risk for skin cancer, 60% of dermatologists reported performing TBSE annually, with 34% performing TBSE every 6 months. In addition, in the high-risk population, 4% performed TBSE every 3 to 4 months, 2% performed TBSE every 2 to 3 years, and 1% of dermatologists reported rarely or never performing TBSE.
The majority of dermatologists reported screening patients by TBSE at least every 2 to 3 years if not annually. In addition, those at increased risk of skin cancer were predominantly screened at least annually, if not every 6 months. Screening frequency was not associated with dermatologist gender, practice location, number of years in practice, or practice environment, with the exception of female practitioners and younger providers (with \5 years of practice experience) who screened those at normal risk for skin cancer more frequently (P ¼ .00004 and P ¼ .004, respectively).
Limitations of this study include selection bias, as those who responded to this survey may have been more interested in this topic, recall bias, which may account for inaccuracy or incompleteness of participant's responses, and finally systemic bias through which participants may have reported more screening than actually performed.
There are no national guidelines regarding frequency of routine TBSE. This survey suggests that the majority of dermatologists routinely perform TBSE in patients at low risk every 2 to 3 years and more frequently in patients at high risk. These data suggest a uniform practice of skin cancer screening in the United States across the broad and diverse population of dermatologists. To the Editor: Nonmelanoma skin cancer (NMSC) is more common than all other cancers combined in the United States, and despite low mortality, their management is associated with significant cost. Questions have been raised regarding appropriate treatment in patients with limited life expectancy, and the best way to determine which patients fall into this category. 1 Prioritizing comorbidity rather than age may be preferred for informing treatment decisions in the very elderly.
A systematic review of the literature was conducted to identify comorbidity instruments used in the NMSC population. Squamous and basal cell carcinoma were included, whereas Merkel cell carcinoma or adnexal tumors were excluded, given the inherently different natural history of these lesions. A total of 2608 titles and 1407 abstracts were identified, of which 22 studies used a comorbidity assessment tool.
Three comorbidity assessment tools in the localized NMSC population were identified: the Charlson Comorbidity Index (CCI), the American Society of Anesthesiologists (ASA) risk classification system, and the Adult Comorbidity Evaluation (ACE)-27 (Table I) . The CCI was the most commonly used in 18 studies involving the NMSC population, and offers the advantages of extensive use and validation in additional cancer populations (Supplemental Table I ; available at http://www.jaad.org). The CCI was shown to predict life expectancy in nonagenarians who had NMSC treated by Mohs micrographic surgery. 2 An additional study in a Department of Veterans Affairs population showed an association between increased CCI score and death. 3 Dhiwakar and colleagues 4 showed a significantly higher CCI score in a group of patients older than 80 years with head and neck skin tumors, compared with patients younger age 80 years. However, a separate study of patients aged 90 years and older undergoing Mohs micrographic surgery did not show a correlation between CCI score and life expectancy after Mohs micrographic surgery. 5 The ASA risk classification was developed in an attempt to define operative risk, and was used Table I ). The ASA, although not formally developed as a comorbidity index, was used for decades preoperatively to predict risk in patients undergoing general anesthesia, and performed comparably with formal indices as a comorbidity measure. 6 An advantage of the ASA is its widespread use in patients who have undergone general anesthesia, many of whom may have this information documented in presurgical paperwork.
The ACE-27 is a modification of the KaplanFeinstein Index and was used in 2 studies in the localized skin cancer population, showing superior performance to a standard medical interview in identifying comorbidity, and a correlation between more severe comorbidity and lower survival 7, 8 (Supplemental Table I ). The ACE-27 includes more comorbid conditions than the CCI and was designed specifically for a cancer population. Both the CCI and the ACE-27 allow investigators to calculate scores retrospectively through medical chart review. They have also been adapted into the form of patientreported questionnaires for ease of data collection.
Although 3 comorbidity measures were identified for the NMSC population, studies are small and limited by significant heterogeneity. The ACE-27 captures more conditions and allows for comorbidity grading, which is not possible with the CCI. Perhaps the ACE-27 will be more accurate in comorbidity assessment, however, larger studies are needed. As demographics shift to an older population over the next 2 decades, an evidence-based approach to management will depend on better understanding the impact of comorbidity and age on patient outcomes. Comorbidity tools may facilitate the decision-making process for physicians and patients, however, further studies are needed to better define their role. To the Editor: Actinic keratoses (AKs) are common, are costly, and have the potential for malignant transformation to keratinocyte carcinoma (KC), 1 ie, cutaneous basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). We sought to determine predictors of AK in patients with a history of multiple KCs, as AKs are more likely to progress to KC in this high-risk population. Univariable and multivariable analyses using Stata software (StataCorp LP, College Station, TX) were performed to elucidate associations between AK count on the face/ears (assessed by study dermatologists) and demographic/health-related factors (selfreported) and KCs in the past 5 years ( from medical records). Baseline AKs and prior KCs were analyzed in quintiles to minimize impact of extreme values. VA Institutional Review Boards approved both trials, participants gave written consent, and Declaration of Helsinki protocols were followed.
